Daxxify (DaxibotulinumtoxinA) Market Report 2026

Daxxify (DaxibotulinumtoxinA) Market Overview

• The Daxxify (DaxibotulinumtoxinA) market growth in the historic period has been driven by high demand for facial aesthetics, widespread botox adoption • Market expansion is supported by increasing aesthetic awareness, growth of non invasive cosmetic procedures • Growth Driver: Rising Demand For Aesthetic Procedures Driving Growth In Daxxify Market • Market Trend: Advancements In Botulinum Toxin Treatments Enhanced Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Daxxify (DaxibotulinumtoxinA) Market?

Daxxify (daxibotulinumtoxinA) is a botulinum toxin type A injectable treatment used for reducing the appearance of moderate to severe glabellar (frown) lines. It is known for its long-lasting effects, with results potentially lasting up to six months or longer. Daxxify is developed by Revance Therapeutics as an alternative to other botulinum toxin treatments such as botox. The main uses of daxxify (daxibotulinumtoxinA) are cosmetic and therapeutic. Cosmetics refer to products used to enhance or alter a person's appearance, including skincare, haircare, and makeup. Daxxify (DaxibotulinumtoxinA) is used in cosmetic treatments to reduce the appearance of wrinkles by temporarily paralyzing the facial muscles, providing smoother skin. Distribution occurs through various channels, such as direct sales and online pharmacies, with end users including medical aesthetic clinics, dermatology practices, and plastic surgery centers.

What Is The Daxxify (DaxibotulinumtoxinA) Market Growth Forecast?

The growth in the forecast period can be attributed to increasing aesthetic awareness, growth of non invasive cosmetic procedures, expansion of premium injectables, rising disposable income, longer duration treatment preference. Major trends in the forecast period include growing demand for long lasting aesthetic injectables, preference for reduced treatment frequency, expansion of medical aesthetic clinics, rising male and younger patient adoption, innovation in botulinum toxin formulations.

Global Daxxify (DaxibotulinumtoxinA) Market Segmentation

1) By Use: Cosmetic Use, Therapeutic Use 2) By Distribution Channel: Direct Sales, Online Pharmacies 3) By End User: Medical Aesthetic Clinics, Dermatology Practices, Plastic Surgery Centers

What Is The Driver Of The Daxxify (DaxibotulinumtoxinA) Market?

The increasing desire for aesthetic procedures is expected to propel the growth of the daxxify (daxibotulinumtoxinA) market going forward. Aesthetic procedures are medical or cosmetic surgical and non-surgical treatments designed to enhance appearance by improving features, reducing signs of aging, and addressing cosmetic concerns, such as botox, fillers, liposuction, and facelifts. The increasing demand for daxxify is due to aging populations, rising aesthetic awareness, advancements in botulinum toxin technology, and growing disposable incomes, leading to higher adoption rates and expanded treatment applications. Daxxify (daxibotulinumtoxinA) helps in aesthetic procedures as it is an effective treatment that temporarily relaxes facial muscles, reducing the appearance of wrinkles and fine lines, enhancing the skin’s smoothness and youthful look, and providing longer-lasting results compared to traditional botulinum toxin treatments. For instance, in April 2025, according to the British Association of Aesthetic Plastic Surgeons, a UK-based surgical organization, between 2023 and 2024, cosmetic surgical procedures increased by 5%, reaching a total of 27,462 procedures performed in 2024. Therefore, the increasing desire for aesthetic procedures is driving growth in the daxxify (daxibotulinumtoxinA) industry.

Key Players In The Global Daxxify (DaxibotulinumtoxinA) Market

Major companies operating in the daxxify (daxibotulinumtoxina) market are Crown Laboratories Inc. (Revance Therapeutics Inc.)

Global Daxxify (DaxibotulinumtoxinA) Market Trends and Insights

Major companies operating in the daxxify (daxibotulinumtoxina) market are focusing on developing innovative treatments, such as Revance’s peptide exchange technology (PXT), to provide longer-lasting and highly effective solutions for aesthetic procedures. Peptide exchange technology (PXT) refers to a proprietary method that enhances the stability and duration of botulinum toxin treatments, resulting in smoother skin, reduced signs of aging, and fewer treatments per year. For instance, in September 2024, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., a China-based pharmaceutical company, received approval from the National Medical Products Administration (NMPA) for daxxify (daxibotulinumtoxinA-lanm) in China. Developed using Revance Therapeutics’ peptide exchange technology, daxxify is the world’s first and only peptide-powered botulinum toxin product, free from human serum albumin and animal-based components, offering improved stability, safety, and long-acting neuromodulation for aesthetic applications.

What Are Latest Mergers And Acquisitions In The Daxxify (DaxibotulinumtoxinA) Market?

In August 2024, Crown Laboratories Inc., a US-based pharmaceutical company, acquired Revance Therapeutics Inc. for $924 million. With this acquisition, Crown Laboratories Inc. aims to expand its portfolio in the aesthetic and pharmaceutical markets by integrating Revance Therapeutics Inc.'s innovative botulinum toxin product, Daxxify (DaxibotulinumtoxinA), and leveraging Revance's expertise in neuromodulators, thereby enhancing Crown's position in the competitive field of non-surgical aesthetic treatments and advancing its growth potential through the addition of advanced therapies for both dermatological and neurological conditions. Revance Therapeutics Inc. is a US-based biotechnology company that manufactures daxxify (daxibotulinumtoxinA).

Regional Insights

North America was the largest region in the daxxify (daxibotulinumtoxinA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Daxxify (DaxibotulinumtoxinA) Market?

The daxxify (daxibotulinumtoxinA) market consists of sales of products such as daxxify for injection 100 units/vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Daxxify (DaxibotulinumtoxinA) Market Report 2026?

The daxxify (daxibotulinumtoxina) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the daxxify (daxibotulinumtoxina) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.